Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-617-S0456
- Development stage
- Unknown
- Lead developer
- Xijing Hospital
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PSMA-617-S0456 is a dual-modality molecular probe designed for the targeted imaging of prostate cancer. It consists of the PSMA-617 ligand, which binds with high affinity to Prostate-Specific Membrane Antigen (PSMA), conjugated to the near-infrared fluorescence (NIRF) dye S0456 and the chelator DOTA. When labeled with Gallium-68 (68Ga), the probe enables preoperative PET/CT imaging to localize primary tumors and metastases. During surgery, the S0456 component provides real-time intraoperative fluorescence guidance, assisting surgeons in performing robot-assisted radical prostatectomy and identifying positive surgical margins or lymph node metastases. The agent is being evaluated in clinical trials at Xijing Hospital of the Airforce Medical University for its safety, feasibility, and diagnostic performance in patients with localized or locally advanced prostate cancer.
- Other names
- DOTA-PSMA-617-S0456DOTA-PSMA617-S0456DOTA-PSMA 617-S045668Ga-PSMA-617-S0456
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-617-S0456.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-617-S0456.